全球肝癌診斷市場規模、佔有率、趨勢和成長分析報告（2026-2034年）

預計肝癌診斷市場將從 2025 年的 109.6 億美元成長到 2034 年的 206.4 億美元，2026 年至 2034 年的複合年成長率為 7.29%。

肝癌診斷市場正經歷顯著成長，這主要得益於肝癌發病率的上升以及人們對早期檢測和診斷意識提升。由於肝炎感染疾病、飲酒和肥胖等因素導致全球肝癌負擔持續加重，高效診斷解決方案的需求也隨之激增。磁振造影(MRI)、超音波斷層掃描 (CT) 和超音波等影像診斷技術的創新提高了肝癌檢測的準確性和靈敏度，使醫療專業人員能夠在更早期、治療效果更佳的階段識別腫瘤。

此外，生物標記研究的進展正在改變肝癌診斷領域。識別與肝癌相關的特定生物標記物，為開發有助於早期診斷和監測疾病進展的非侵入性血液檢測鋪平了道路。這些檢測不僅減輕了患者的負擔，也減少了侵入性手術的需求，因此對患者和醫療服務提供者都極具吸引力。對個人化醫療日益成長的關注，進一步推動了對能夠根據個別患者情況量身定做治療策略的先進診斷工具的需求。

此外，對預防醫學和篩檢計畫的日益重視也推動了肝癌診斷市場的成長。隨著醫療機構對高風險族群進行常規篩檢，可靠診斷解決方案的需求預計將會增加。研究機構、診斷設備製造商和醫療服務提供者之間的合作正在促進創新，並加速新型診斷技術的研發。總之，肝癌診斷市場預計將呈現強勁成長，其特點是技術進步、注重早期檢測以及透過有效的診斷解決方案改善患者預後。

目錄

第1章 引言

第2章執行摘要

第3章 市場變數、趨勢與框架

• 市場譜系展望
• 繪製滲透率和成長前景圖
• 價值鏈分析
• 法律規範
  • 標準與合規性
  • 監管影響分析
• 市場動態
  • 市場促進因素
  • 市場限制
  • 市場機遇
  • 市場問題
• 波特五力分析
• PESTLE分析

第4章 全球肝癌診斷市場（依檢測類型分類）

• 市場分析、洞察與預測
• 實驗室檢測
• 影像診斷
• 內視鏡檢查
• 切片檢查
• 其他

5. 全球肝癌診斷市場依最終用途分類

• 市場分析、洞察與預測
• 醫院和診斷實驗室
• 學術研究機構
• 製藥公司和CRO實驗室

6. 全球肝癌診斷市場（依地區分類）

• 區域分析
• 北美市場分析、洞察與預測
  • 美國
  • 加拿大
  • 墨西哥
• 歐洲市場分析、洞察與預測
  • 英國
  • 法國
  • 德國
  • 義大利
  • 俄羅斯
  • 其他歐洲國家
• 亞太市場分析、洞察與預測
  • 印度
  • 日本
  • 韓國
  • 澳洲
  • 東南亞
  • 其他亞太國家
• 拉丁美洲市場分析、洞察與預測
  • 巴西
  • 阿根廷
  • 秘魯
  • 智利
  • 其他拉丁美洲國家
• 中東和非洲市場分析、洞察與預測
  • 沙烏地阿拉伯
  • UAE
  • 以色列
  • 南非
  • 其他中東和非洲國家

第7章 競爭情勢

• 最新趨勢
• 公司分類
• 供應鏈和銷售管道合作夥伴（根據現有資訊）
• 市場佔有率和市場定位分析（基於現有資訊）
• 供應商格局（基於現有資訊）
• 策略規劃

第8章：公司簡介

• 主要公司的市佔率分析
• 公司簡介
  • Abbott Laboratories
  • F. Hoffmann-La Roche Ltd
  • Qiagen NV
  • Thermo Fisher ScientificInc
  • Siemens Healthineers
  • Becton Dickinson & Company
  • IlluminaInc
  • Koninklijke Philips NV
  • Epigenomics AG
  • Fujifilm Medical Systems USAInc

The Liver Cancer Diagnostic Market size is expected to reach USD 20.64 Billion in 2034 from USD 10.96 Billion (2025) growing at a CAGR of 7.29% during 2026-2034.

The liver cancer diagnostic market is experiencing significant growth, driven by the increasing incidence of liver cancer and the rising awareness of early detection and diagnosis. As the global burden of liver cancer continues to escalate, fueled by factors such as hepatitis infections, alcohol consumption, and obesity, the demand for effective diagnostic solutions is surging. Innovations in imaging techniques, such as magnetic resonance imaging (MRI), computed tomography (CT), and ultrasound, are enhancing the accuracy and sensitivity of liver cancer detection, enabling healthcare providers to identify tumors at earlier stages when treatment options are more effective.

Moreover, advancements in biomarker research are transforming the liver cancer diagnostic landscape. The identification of specific biomarkers associated with liver cancer is paving the way for the development of non-invasive blood tests that can aid in early diagnosis and monitoring of disease progression. These tests not only improve patient comfort but also reduce the need for invasive procedures, making them an attractive option for both patients and healthcare providers. The growing emphasis on personalized medicine is further driving the demand for advanced diagnostic tools that can tailor treatment strategies based on individual patient profiles.

Additionally, the increasing focus on preventive healthcare and screening programs is contributing to the growth of the liver cancer diagnostic market. As healthcare organizations implement routine screening for high-risk populations, the demand for reliable diagnostic solutions is expected to rise. The collaboration between research institutions, diagnostic companies, and healthcare providers is fostering innovation and accelerating the development of new diagnostic technologies. In summary, the liver cancer diagnostic market is set for robust growth, characterized by technological advancements, a focus on early detection, and a commitment to improving patient outcomes through effective diagnostic solutions.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Test Type

• Laboratory Tests
• Imaging
• Endoscopy
• Biopsy
• Others

By End-use

• Hospitals & Diagnostic Laboratories
• Academic & Research Institutes
• Pharmaceutical & CRO Laboratories

COMPANIES PROFILED

• Abbott Laboratories, F HoffmannLa Roche Ltd, Qiagen NV, Thermo Fisher Scientific, Inc, Siemens Healthineers, Becton Dickinson Company, Illumina, Inc, Koninklijke Philips NV, Epigenomics AG, Fujifilm Medical Systems USA, Inc

We can customise the report as per your requriements

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL LIVER CANCER DIAGNOSTIC MARKET: BY TEST TYPE 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Test Type
• 4.2. Laboratory Tests Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Imaging Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Endoscopy Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.5. Biopsy Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.6. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL LIVER CANCER DIAGNOSTIC MARKET: BY END-USE 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast End-use
• 5.2. Hospitals & Diagnostic Laboratories Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Academic & Research Institutes Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Pharmaceutical & CRO Laboratories Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL LIVER CANCER DIAGNOSTIC MARKET: BY REGION 2022-2034(USD MN)

• 6.1. Regional Outlook
• 6.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.2.1 By Test Type
  • 6.2.2 By End-use
  • 6.2.3 United States
  • 6.2.4 Canada
  • 6.2.5 Mexico
• 6.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.3.1 By Test Type
  • 6.3.2 By End-use
  • 6.3.3 United Kingdom
  • 6.3.4 France
  • 6.3.5 Germany
  • 6.3.6 Italy
  • 6.3.7 Russia
  • 6.3.8 Rest Of Europe
• 6.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.4.1 By Test Type
  • 6.4.2 By End-use
  • 6.4.3 India
  • 6.4.4 Japan
  • 6.4.5 South Korea
  • 6.4.6 Australia
  • 6.4.7 South East Asia
  • 6.4.8 Rest Of Asia Pacific
• 6.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.5.1 By Test Type
  • 6.5.2 By End-use
  • 6.5.3 Brazil
  • 6.5.4 Argentina
  • 6.5.5 Peru
  • 6.5.6 Chile
  • 6.5.7 South East Asia
  • 6.5.8 Rest of Latin America
• 6.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.6.1 By Test Type
  • 6.6.2 By End-use
  • 6.6.3 Saudi Arabia
  • 6.6.4 UAE
  • 6.6.5 Israel
  • 6.6.6 South Africa
  • 6.6.7 Rest of the Middle East And Africa

Chapter 7. COMPETITIVE LANDSCAPE

• 7.1. Recent Developments
• 7.2. Company Categorization
• 7.3. Supply Chain & Channel Partners (based on availability)
• 7.4. Market Share & Positioning Analysis (based on availability)
• 7.5. Vendor Landscape (based on availability)
• 7.6. Strategy Mapping

Chapter 8. COMPANY PROFILES OF GLOBAL LIVER CANCER DIAGNOSTIC INDUSTRY

• 8.1. Top Companies Market Share Analysis
• 8.2. Company Profiles
  • 8.2.1 Abbott Laboratories
  • 8.2.2 F. Hoffmann-La Roche Ltd
  • 8.2.3 Qiagen N.V
  • 8.2.4 Thermo Fisher ScientificInc
  • 8.2.5 Siemens Healthineers
  • 8.2.6 Becton Dickinson & Company
  • 8.2.7 IlluminaInc
  • 8.2.8 Koninklijke Philips N.V
  • 8.2.9 Epigenomics AG
  • 8.2.10 Fujifilm Medical Systems U.S.A.Inc